Siemens Unveils MR Oncology Applications and Dedicated Breast ... International Business Times, NY - Nov 30, 2008 With prostate cancer as the second leading cause of cancerdeath in American men, MR plays a vital role in determining which men are atserious risk. ...
Health calendar Monroe News Star, LA - Prostate Cancer ? 6:30 to 7:30 pm fourth Tuesday of every month, Glenwood Medical Mall Community Room, 102 Thomas Road, West Monroe. Jimmy Craft, 343-1446. ...
Hadassah focuses on inherited cancer risk St.Louis Jewishlight.com, MO - Nov 29, 2008 Ivanovich outlined the steps in determining if a family has a genetic cancer risk. The first step is to look at family history of cancer, and make a chart ...
The FDA's Black Box Forbes, NY - 41 minutes ago Last year the agency rejected a prostate cancer treatment called Provenge from Dendreon (nasdaq: DNDN - news - people ) after an advisory panel voted 13-4 ...SGP - OTC:SHRGY
Wheeling Doctor Receiving National Attention State Journal, WV - If you would like to check out brachytherapy or have any questions about preventing prostate cancer you can log onto this website at www dot great prostate...
Lonely lord tries to flog himself on web Herald.ie, Ireland - Now he is selling his lifestyle on the internet auction website eBay because he said he had been diagnosed with advanced prostate cancer. ...
? Ron Lancaster battling cancer Hamilton Spectator, Canada - Ron Lancaster, who recently wrestled prostate cancer to a standstill, is suffering from cancer again. The former coach and general manager of the Hamilton ...
Widow Works to Make Life Better for Prostrate Cancer Families RedOrbit, TX - Aug 5, 2008 4--After losing her husband, Kenny, to prostate cancer three years ago today, Sherrie Ellenburg is on a crusade to make life better for wives whose husbands ...
EDAP Launches Enhanced Web Site MarketWatch - Jul 31, 2008 Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an ...EDAP
Gene expression profiling identifies clinically relevant subtypes of prostate cancer - J Lapointe - Proceedings of the National Academy of Sciences, 2004 - National Acad Sciences ... with tumor recurrence, our data suggest that at least in prostatecancer, this
metastatic ... 7, which is published as supporting information on the PNAS web site ...
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11. 2 - JT Dong, PW Lamb, CW Rinker-Schaeffer, J Vukanovic … - Science, 1995 - sciencemag.org ... that you are using a browser that does not support current Web standards. ... KAI1, a
metastasis suppressor gene for prostatecancer on human chromosome 11p11.2. ...
Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer - RE Reiter, Z Gu, T Watabe, G Thomas, K Szigeti, E … - Proceedings of the National Academy of Sciences, 1998 - National Acad Sciences Vol. 95, Issue 4, 1735-1740, February 17, 1998. Medical Sciences Prostate stem cell
antigen: A cell surface marker overexpressed in prostatecancer. ...
Growth factor involvement in progression of prostate cancer - PJ Russell, S Bennett, P Stricker - Clinical Chemistry, 1998 - Am Assoc Clin Chem ... Review. Growth factor involvement in progression of prostatecancer. Pamela
J. Russell 1 ,a , Suzanne Bennett 1 , and Phillip Stricker 2 ...
[CITATION] Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer - HB Carter, JI Epstein, DW Chan, JL Fozard, JD … - JAMA: The Journal of the American Medical Association, 1997 - JAMA ... message because your Web browser does not support basic Web standards. ...prostate-specific
antigen testing intervals for the detection of curable prostatecancer. ...
Source: Google Scholar
Antioxidant supplementation not associated with decreased risk of prostate cancer
Intakes of dietary or supplemental antioxidants were not associated with a decreased risk of prostate cancer among men in the Prostate, Lung, Colorectal, and Ovarian ( PLCO ) Cancer Screening Trial.
The study did find that vitamin E and beta-carotene supplementation may be associated with reduced prostate cancer risk in certain population subgroups.
Research suggests that micronutrients such as vitamin E, vitamin C, and carotenoids may play a role in preventing cancer development because of their ability to combat free radicals, agents that can damage cellular DNA, lipid membranes, and proteins.
In many studies, vitamin E has been associated with a reduced risk of prostate cancer, and beta-carotene has been associated with increased lung cancer risk in previous studies. However, no studies have examined associations between intakes of these three antioxidant micronutrients and the risk of prostate cancer.
Richard B. Hayes, at the National Cancer Institute, and colleagues assessed the risk of prostate cancer for 29,361 men ages 55 to 74 enrolled in the PLCO Cancer Screening Trial, based on their daily intake of beta-carotene, vitamin E, and vitamin C.
The researchers looked at intake of antioxidants from both dietary sources and from supplements.
The authors found that, overall, dietary or supplemental intake of vitamin E, vitamin C, or beta-carotene was not associated with prostate cancer incidence in this group of PLCO trial participants. However, certain micronutrients were associated with prostate cancer risk in specific subgroups of men. For current or recent smokers, high-dose, long-duration vitamin E supplementation was associated with a reduced risk of advanced prostate cancer. For men with a low dietary intake of beta-carotene, high-dose supplements of beta-carotene were associated with a reduced risk of prostate cancer.
" Our cohort findings, although based on relatively short follow-up, do not provide strong support for population-wide implementation of high-dose antioxidant supplementation for the prevention of prostate cancer," the authors write. " They do suggest, however, that in certain population subgroups there was an association between supplement intake and reduced risks of prostate cancer."
In an accompanying editorial, I-Min Lee, of Brigham and Women's Hospital in Boston, and colleagues discuss the implications of Hayes and colleagues' study in the context of earlier studies of vitamin E supplementation and cancer risk.
The editorialists agree that the study results do not provide strong support for the implementation of antioxidant supplementation for the prevention of prostate cancer.
They note that the data remain unclear about the benefits of vitamin E supplementation for prostate cancer prevention in the general population; however, there are strong data supporting smoking cessation to reduce cancer incidence.
The authors write, " Now and in the future, regardless of the eventual findings on vitamin E supplementation and prostate cancer risk, an important course of action for overall cancer prevention is to continue efforts to prevent the initiation of smoking and to promote the cessation of smoking among those who do smoke."
Source: Journal of the National Cancer Institute, 2006